Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1

Inclusion Criteria for Parts A and B: * Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. * Willing to provide written informed consent and to comply with study requirements. Additional Inclusion Criteria for Part B: * Confirmation of PH1 disease * Meet 24 hour urine oxalate excretion requirements * Estimated glomerular filtration rate (GFR) of \>45 mL/min/1.73m\^2 * If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days Exclusion Criteria for Parts A and B: * Clinically significant health concerns (with the exception of PH1 for patients in Part B) * Clinically significant electrocardiogram (ECG) abnormalities * Abnormal for aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and any other clinical safety laboratory result considered clinically significant * Received an investigational agent within 3 months before the first dose of study drug or are in follow-up of another clinical study * Known history of allergic reaction to an oligonucleotide or N-acetylgalactosamine (GalNAc) * History of intolerance to subcutaneous injection